ClinicalTrials.gg
RecruitingNCT06858774Updated Apr 20, 2026

Use of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder

An interventional study of Circadian Reset Technology and VR Headset in Binge-Eating Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 122 studies in Binge-Eating Disorder with a site in United States — 19 open to participants now, 26 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Planned enrollment
74th of 112
40 · median 67
Started
2025
with 9 others
No phase
64 of 122
14 open now
Primary completion
2026-11
later than 4 of 25 live
Registered
111th of 122
by date
Lead sponsor
3 of 122
Icahn School of Medicine at Mount Sinai

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 74th largest by planned enrollment of the 112 interventional ones that give a count, is one of 10 that started in 2025, is one of 64 with no phase, reaches primary completion later than 4 of the 25 other live ones, and was the 111th registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 50 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

19 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 22 (67%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

This project includes testing circadian reset technology (CRT) on frequency of binge eating in a sample of 40 individuals with binge eating disorder. Participants will be randomized to one of two groups. Both groups use a virtual reality (VR) headset for 10 minutes (5 upon waking, 5 before sleep) daily for 1 month. One group will use the CRT software on the headset and the other group will use a software intended to be a control. Measures will be taken at baseline and 1-month. The researchers anticipate that use of CRT will improve sleep quality leading to increased appetitive control.

Read the detailed description

This is a clinical trial with total of 40 individuals with Binge Eating Disorder ages 18 or older will be enrolled to use a VR headset with CRT or without. Examine whether 1-month of CRT alters binge eating frequency. Secondary outcomes include examining whether 1-month of CRT alters sleep quality, appetite regulation, functional magnetic resonance imaging (fMRI) measures of functional connectivity, food-based impulsivity/craving, and mood. Assessments are completed at baseline, weekly for 1 month, and then a final 1-month follow-up. Procedures include a screening/baseline phase to determine eligibility, gather baseline measures, and set-up on VR headset. Weeks 1 through 4 include using a VR headset twice a day for 5 minutes each. An online weekly survey will be completed, as well as daily ecological momentary assessment (EMA) surveys related to eating patterns throughout each day. The final visit will include a repeat of the baseline procedures including the fMRI. All recruitment and study procedures will take place through the Center of Excellence in Eating and Weight Disorders at the Icahn School of Medicine at Mount Sinai.

03

Conditions studied

  • Binge-Eating Disorder

Keywords

  • Binge Eating Disorder
  • Eating Disorder
  • Eating Disorder Treatment
  • Circadian Rhythm Technology
  • Virtual Reality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18+
  • Diagnosed with Binge Eating Disorder using EDA-5
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Acute suicide risk/active suicidal ideation
  • PSQI score \<5 indicating good sleep quality
  • A condition that may create a risk while using the VR headset including risk of falls, seizures, a heart condition, migraines, an eye or vision condition, or an inner ear condition.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Circadian Reset Technology

    Participants will be given the headset to use for 5 minutes twice a day for 1 month while sitting in a resting position. Use will be separated by 12-16 hours of wakefulness.

    Behavioral: Circadian Reset Technology

  • Sham comparator
    VR Headset

    Participants will be given a headset to use for 5 minutes twice a day for 1 month while sitting in a resting position. Use will be separated by 12-16 hours of wakefulness.

    Behavioral: VR Headset

Interventions

  • BehavioralCircadian Reset Technology

    Circadian reset technology is a software used on a VR headset in this intervention. The software is a passive viewing experience like a guided meditation that presents visual images.

  • BehavioralVR Headset

    The software used on a VR headset in this intervention is a passive viewing experience like a guided meditation that presents neutral images that mimics the sequence used in the CRT software.

06

What researchers measure

Primary outcomes

  1. Change in the total number of bulimic episodes

    Binge eating frequency measured by Eating Disorder Examination Questionnaire (EDE-Q). The EDE-Q scores behavioral features of eating disorders by calculating the number of episodes and number of days on which the behavior occurs. The total number of bulimic episodes will be measured to determine binge-eating frequency. Scores will be calculated between baseline and 1 month. The EDE-Q is a 28-item self-report measure assessing eating disorder symptoms. Full scale from 0-6, with higher score indicates greater severity of eating disorder symptoms.

    Time frame: Baseline to 1-month

Secondary outcomes

  1. Change in Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality measured by Pittsburgh Sleep Quality Index (PSQI) is a 19-item assessment that measures sleep quality with questions about duration, latency, frequency/severity of sleep issues. Items are answered on a scale of 0-3. The final score is a total of all questions ranging from 0 to 21 with lower score indicating worse sleep quality and higher score indicating better sleep quality. Scores will be calculated between baseline and 1 month.

    Time frame: Baseline to 1-month

  2. Change in Three-Factor Eating Questionnaire (TFEQ)

    Appetite regulation (restrained eating, disinhibited eating, and predisposition to hunger) measured by Three-Factor Eating Questionnaire (TFEQ) assesses appetite using 51 questions summarized in 3 subscales: cognitive restraint, uncontrolled eating, and emotional eating. Each item is scored as 0 or 1 and then summed. Subscales Cognitive restraint of eating score 0-21, Disinhibition score 0-16, and Hunger score 0-14. Full scale scored 0-51, higher scores indicate higher levels of restrained eating. Scores will be calculated between baseline and 1 month.

    Time frame: Baseline to 1-month

  3. Changes in default mode network

    Change in Brain functional connectivity as measured by default mode network - This test measures the pattern of connectivity in the default mode network during rest. Strength of connectivity default mode network (DMN) will estimated at the network level and between individual nodes.

    Time frame: Baseline to 1-month

  4. Change in Eating Loss of Control Scale (ELOCS)

    Food-based impulsivity measured by Eating Loss of Control Scale (ELOCS) measures the degree to which eating episodes included the feeling of loss of control measured continuously over the prior 4-weeks. There are 18 items scored on 0-10 scale from "not at all" to "Extremely/Completely". For total score, severity questions are averaged to get a mean severity score ranging between 0-10. Higher scores indicate more loss of control. Scores will be calculated between baseline and 1 month. Baseline to 1-month

    Time frame: Baseline to 1-month

  5. Change in Food Cravings Questionnaire-Trait (FCQ-T)

    Food-based cravings (Trait) measure by Food Cravings Questionnaire-Trait (FCQ-T) is 39 items on a scale of 1 (never/NA) to 6 (always) with a total summed score ranging from 39 to 234 with higher scores indicating more frequent and intense food cravings. Scores will be calculated between baseline and 1 month.

    Time frame: Baseline to 1-month

  6. Change in Food Cravings Questionnaire-State (FCQ-S)

    Food-based cravings (State) measured by Food Cravings Questionnaire-State (FCQ-S) has 15 items on a scale of 1 (strongly disagree) to 5 (strongly agree) with a total summed score ranging from 15 to 75 with higher scores indicating more intense food cravings. Scores will be calculated between baseline and 1 month.

    Time frame: Baseline to 1-month

  7. Change in Depression Anxiety and Stress Scale (DASS)

    Depression Anxiety and Stress Scale (DASS) includes 42 questions that assess negative mood using subscales of depression, anxiety, and stress. Each subscale is scored 0-42, with total score from 0-126, higher score indicates poorer health outcomes. The depression scale scores are 0-9 (Normal), 10-13 (Mild), 14-20 (Moderate), 21-27 (Severe), and 28+ (Extremely Severe). The anxiety scale scores are 0-7 (Normal), 8-9 (Mild), 10-14 (Moderate), 15-19 (Severe), and 20+ (Extremely Severe). The stress scale scores are 0-14 (Normal), 15-18 (Mild), 19-25 (Moderate), 26-33 (Severe), and 34+ is (Extremely Severe).

    Time frame: Baseline to 1-month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared from this trial due to the early stages of investigation.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 81 non-industry interventional studies with no phase under Binge-Eating Disorder, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 18 months is below that.

Counting every sponsor, half of 86 studies reached it within 25 months; a quarter within 16 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 5, 2025
StartActual
May 13, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06858774
Responsible party
Tom Hildebrandt (Professor and Chief of the Division of Eating & Weight Disorders, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Mar 5, 2025
Start date
May 13, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 20, 2026

Study contacts

Tom Hildebrandt
Contact
tom.hildebrandt@mssm.edu
212-659-8673
Jessica Bibeau
Contact
jessica.bibeau@mssm.edu
212-659-8673
Tom Hildebrandt
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion